Welcome to the CRYSVITA® website for Australian HCPs
크리스비타® (burosumab) is indicated for the treatment of X-linked hypophosphataemia (XLH) in adults, adolescents and children 1 year of age or older. 1
XLH란 무엇인가요?
XLH is a rare, genetic, progressive and life-long phosphate wasting disorder, caused by mutations in the PHEX gene that leads to excess FGF232–7
크리스비타는 어떻게
작용하나요?
크리스비타® is a recombinant human monoclonal IgG1 antibody that binds to and inhibits the biological activity of fibroblast growth factor 23 (FGF23), present in excess in X-linked hypophosphataemia. Neutralisation of FGF23 by CRYSVITA® increases renal tubular reabsorption of phosphate and the serum concentration of 1, 25 dihydroxy-Vitamin D. 1
왜 크리스비타를 투여해야 하나요?®?
크리스비타의® in children (aged ≥1 year) and adults with XLH has been studied in a global clinical development programme, comprising phase II and phase III clinical trials 8-13
크리스비타는 어떻게 투여하나요?®
크리스비타® is indicated for the treatment of X-linked hypophosphataemia (XLH) in adults, adolescents and children 1 year of age or older.1
XLH 환자 진료에 도움이 될 수 있는 자료
Resources include a Dosing and Administration Guide, Injection Guide, Prescribing Guide, Patient Starter Guide and more.
Adverse Event Reporting:
Australian regulations require that matters potentially impacting patient safety, including suspected adverse events and side effects are documented and reported. Information reported shall be managed in accordance with Australian Privacy Law and regulations laid out by the Therapeutic Goods Administration (TGA) of Australia. To report such matters, please e-mail …
1. Australian Product Information for Crysvita® (burosumab) approved 10 September 2021. https://www.kyowakirin.com/australia/our_medicines/doc/crysvita_product_information_leaflet.pdf. Last updated: Sept 2021 Last accessed: March 2023. 2. Beck-Nielsen SS, et al. Orphanet J Rare Dis. 2019;14:58. 3. Carpenter TO, et al. J Bone Miner Res. 2011;26:1381–88. 4. Endo I, et al. Endocr J. 2015;62:811–16. 5. Haffner D, et al. Nat Rev Nephrol. 2019;15:435–55. 6. Martin A & Quarles LD. Adv Exp Med Biol. 2012;728:65–83. 7. Rafaelsen S, et al. Eur J Endocrinol. 2016;174:125–36 8. Carpenter TO, et al. N Engl J Med. 2018;378:1987-98. 9. Whyte MP, et al. Lancet Diabetes Endocrinol 2019;7:189-99. 10. Imel EA, et al. Lancet. 2019;393:2416–27. 11. Insogna KL, et al. J Bone Miner Res. 2018;33:1383–93. 12. Portale AA, et al. Calcif Tissue Int. 2019;105:271–84. 13. Insogna KL, et al. J Bone Miner Res. 2019;34:2183–91.
